189 Jaksot

  1. Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

    Julkaistiin: 25.3.2025
  2. Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

    Julkaistiin: 20.2.2025
  3. Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

    Julkaistiin: 10.2.2025
  4. Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

    Julkaistiin: 9.1.2025
  5. Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

    Julkaistiin: 22.10.2024
  6. Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

    Julkaistiin: 16.10.2024
  7. ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

    Julkaistiin: 1.10.2024
  8. A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

    Julkaistiin: 30.9.2024
  9. Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

    Julkaistiin: 6.9.2024
  10. Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

    Julkaistiin: 5.9.2024
  11. ROS1-Alterations and Molecular Testing in Advanced NSCLC

    Julkaistiin: 28.8.2024
  12. Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

    Julkaistiin: 5.8.2024
  13. Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

    Julkaistiin: 22.7.2024
  14. Current Clinical Practice and NCCN Guidelines for CLL/SLL

    Julkaistiin: 18.7.2024
  15. Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

    Julkaistiin: 12.7.2024
  16. CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

    Julkaistiin: 11.7.2024
  17. Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

    Julkaistiin: 9.7.2024
  18. Congress to Clinic: Expert Takeaways on Emerging Data for AML

    Julkaistiin: 8.7.2024
  19. Congress to Clinic: Expert Takeaways on Emerging Data for MDS

    Julkaistiin: 5.7.2024
  20. Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

    Julkaistiin: 14.5.2024

1 / 10

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Visit the podcast's native language site